LiveScience.com – A commonly prescribed arthritis drug has shown promise in preventing some of the most common skin cancers, according to new results of a clinical trial. However, high doses of the drug – celecoxib, also known as Celebrex – have been linked to serious heart problems, and the researchers cautioned that further study is [...]
LiveScience.com – A commonly prescribed arthritis drug has shown promise in preventing some of the most common skin cancers, according to new results of a clinical trial. However, high doses of the drug – celecoxib, also known as Celebrex – have been linked to serious heart problems, and the researchers cautioned that further study is [...]
HealthDay – TUESDAY, Nov. 30 (HealthDay News) — The number of prescriptions for controlled medications such as opioids and stimulants has nearly doubled in adolescents and young adults since 1994.
HealthDay – (HealthDay News) — Here are the latest clinical trials, courtesy of ClinicalConnection.com:
HealthDay – TUESDAY, Nov. 30 (HealthDay News) — Using a computer simulation model, researchers say they’ve determined that relying on „active surveillance” to follow men with low-risk prostate cancer is a „reasonable approach” and alternative to immediate treatment, which can cause unwanted side effects such as incontinence and impotence.
HealthDay – TUESDAY, Nov. 30 (HealthDay News) — The admonishment to parents to carefully follow the directions on the labels of over-the-counter kids’ medicines may be futile, new research suggests.
HealthDay – TUESDAY, Nov. 30 (HealthDay News) — Reduced use of hormone replacement therapy (HRT) is linked to declines in rates of invasive breast cancer and ductal carcinoma in situ, the most common form of noninvasive breast cancer, a new study reports.
Reuters – Older men with low-risk prostate cancer may be better off getting regular check-ups that rushing to get surgery or radiation, researchers using a computer model suggested on Tuesday.
AFP – An experimental drug developed by AstraZeneca to treat a rare form of thyroid cancer carries „substantial toxicity” risks, the US Food and Drug Administration warned Tuesday.
AFP – An experimental drug developed by AstraZeneca to treat a rare form of thyroid cancer carries „substantial toxicity” risks, the US Food and Drug Administration warned Tuesday.